Company news

Incyte Corporation news in 2025

Incyte Corporation's news releases, calls and decks from 2025, newest first.

View company

Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer

December 21, 2025

Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma

December 21, 2025

Incyte to Present at Upcoming Investor Conference

December 17, 2025

Incyte Announces European Commission Approval of Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma

December 16, 2025

Incyte Announces Change to its Board of Directors

December 11, 2025

Incyte Presents Updated Positive Data at ASH 2025 Reinforcing the Potential of INCA033989, its First-in-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Essential Thrombocythemia

December 7, 2025

Incyte’s First-in-Class mutCALR-Targeted Monoclonal Antibody, INCA033989, Granted Breakthrough Therapy Designation by U.S. FDA

December 6, 2025

Incyte Announces New Positive Data for INCA033989, its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Myelofibrosis Presented at ASH 2025

December 6, 2025

Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

December 2, 2025

Incyte and Winnie Harlow Join Forces to Share Her Personal Vitiligo Story and Spark Conversation and Understanding

December 1, 2025

Incyte Appoints Richard Hoffman as Executive Vice President and General Counsel

November 30, 2025

Incyte to Present at Upcoming Investor Conferences

November 18, 2025

Incyte Announces Positive CHMP Opinion for Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma (FL)

November 16, 2025

Incyte’s Moments of Clarity Program Expands to Highlight Powerful Patient Stories in Vitiligo and Pediatric Eczema

November 5, 2025

Incyte Announces More than 50 Abstracts Accepted for Presentation at the 2025 ASH Annual Meeting

November 2, 2025

Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates

October 27, 2025

Incyte and Enable Injections Announce Strategic Partnership for enFuse® On-Body Delivery System

October 26, 2025

Incyte Announces New Data from Phase 3b TRuE-AD4 Trial of Opzelura® (Ruxolitinib Cream) in Adults with Moderate Atopic Dermatitis

October 24, 2025

Lilly's baricitinib delivered near-complete scalp hair regrowth at one year for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS trial

October 24, 2025

Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma

October 18, 2025

Data from Incyte’s TGFβR2×PD-1 Bispecific Antibody and KRAS G12D Inhibitor to be Presented at the European Society of Medical Oncology (ESMO) Congress 2025

October 11, 2025

Incyte to Report Third Quarter Financial Results

October 7, 2025

Incyte Announces the Appointment of Dave Gardner as Executive Vice President and Chief Strategy Officer

September 21, 2025

Incyte Announces Additional FDA Approval of Opzelura® (Ruxolitinib) Cream in Children Ages 2-11 with Atopic Dermatitis

September 17, 2025

Incyte Announces New 24-Week Phase 3 Data from the STOP-HS Clinical Trial Program of Povorcitinib in Hidradenitis Suppurativa at EADV 2025

September 16, 2025

Incyte to Present New Data Highlighting Progress Across its Dermatology Pipeline at the European Association of Dermatology and Venerology 2025 Congress

September 9, 2025

Incyte Launches HS TRUTHS to Spotlight the True Lived Experience of Hidradenitis Suppurativa

September 2, 2025

Incyte Announces the Appointment of Soni Basi as Executive Vice President and Chief Human Resources Officer

August 24, 2025

Incyte Announces Departure of Chief Financial Officer Christiana Stamoulis

August 5, 2025

Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Brazil

July 30, 2025

Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs

July 28, 2025

Incyte To Present Initial Data for its TGFβR2×PD-1-directed Bispecific Antibody (INCA33890) and its Selective Inhibitor of G12D-mutated KRAS (INCB161734) at the European Society of Medical Oncology (ESMO) Congress 2025

July 23, 2025

Incyte to Report Second Quarter Financial Results

July 9, 2025

Incyte Appoints Bill Meury Chief Executive Officer; Hervé Hoppenot to Retire

June 25, 2025

Update on FDA Review of Ruxolitinib Cream (Opzelura®) for Children Ages 2-11 with Atopic Dermatitis

June 19, 2025

Incyte Announces FDA Approval of Monjuvi® (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma

June 17, 2025

QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)

June 14, 2025

Positive Late-Breaking Data for Incyte’s First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025

June 14, 2025

Phase 3 Data for Incyte’s Retifanlimab (Zynyz®) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet

June 11, 2025

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 5, 2025

Incyte Announces Multiple Presentations, Including New Late-Breaking Data for its mutCALR-Directed Monoclonal Antibody (INCA033989), Accepted for Presentation at EHA 2025

June 2, 2025

Incyte Announces FDA Approval of Zynyz® (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States

May 14, 2025

Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs

April 28, 2025

Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 2025

April 24, 2025

Incyte to Showcase New Data from its Oncology Portfolio at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

April 22, 2025

Incyte to Report First Quarter Financial Results

April 9, 2025

Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients With Hidradenitis Suppurativa

March 16, 2025

Lilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS study

March 7, 2025

Incyte Announces Results of Phase 3 Clinical Trials Evaluating Ruxolitinib Cream 1.5% (Opzelura®) in Patients with Prurigo Nodularis (PN) at 2025 American Academy of Dermatology Annual Meeting

March 7, 2025

Incyte to Unveil New Data from its Dermatology Portfolio at 2025 American Academy of Dermatology (AAD) Annual Meeting

February 27, 2025

Older news releases →

Calls in 2025

Decks in 2025